There are no effective treatments for castrate-resistant (CR) prostate cancer (PCa). The work performed during the previous funding cycle provided proof-of-concept for Stat5a/b acting as a critical survival factor for human PCa cells. Inhibition of Stat5a/b leads to extensive death of Stat5-positive human PCa cell lines and blocks prostate xenograft tumor growth in nude mice. We showed that elevated levels of nuclear Stat5a/b in PCa: 1) are associated with high histological grade, 2) predict development of CR recurrent PCa and increased risk of PCa-specific death, 3) are associated with CR PCa and distant metastases and Stat5a/b activation promotes metastatic behavior of PCa cells in vitro and in vivo. Two novel concepts emerged from the work of the previous funding cycle: 1) Synergy between Stat5a/b and androgen receptor (AR)-regulated gene transcription in PCa cells7, 2) Amplification of the Stat5a/b gene locus occurs in up to 30-40% of high grade PCas and 60% of CR PCas. Preliminary progress supports exploration of three independent mechanisms of Stat5-driven growth of CR PCa: i) Stat5a/b up-regulation of full-length AR in PCa cells, ii) Stat5a/b induction of ligand-independent constitutively active AR splice variants, and iii) Stat5a/b stimulation of PCa cell survival independently of AR through Surviving. We will test the central hypothesis: Somatically amplified Stat5a/b promotes CR growth of PCa through AR- dependent and AR-independent mechanisms, and Stat5a/b provides a therapeutic target protein and response-predictive marker for CR PCa. We will pursue three aims: 1) Determine mechanisms of Stat5a/b promotion of castrate-resistant PCa growth. 2) Determine the diagnostic and functional significance of Stat5a/b gene amplification for prostate cancer progression to CR disease and clinical outcome. 3) Determine the efficacy of therapeutic targeting of Stat5a/b pathway in CR prostate cancer. At the completion of this work, we expect to have determined whether Stat5a/b gene amplification, its AR-independent PCa growth promotion and transcriptional co- action with the full length AR and AR splice variants may represent novel mechanisms of CR growth of PCa. This is significant because pharmacological inhibitors of Jak2-Stat5a/b signaling pathway represent rapidly implementable therapeutic strategies for CR PCa. We will determine whether Stat5a/b gene amplification, alone or in combination with AR gene amplification may provide a new predictive marker for identification of patients with PCa likely to progress to CR disease and would benefit from early aggressive intervention. Furthermore, Stat5a/b gene amplification may represent a predictive marker of responsiveness to therapies targeting Jak2-Stat5 signaling pathway. The proposed research may directly impact development of new strategies for improved and individualized therapy for PCa patients.

Public Health Relevance

The objective of this proposal is to explore the therapy-relevant and novel concept that somatically amplified Stat5a/b promotes growth of castrate resistant (CR) prostate cancer (PCa) through AR-dependent and AR- independent mechanisms. At the completion of this work, we expect to have determined whether Stat5a/b gene amplification, its AR-independent PCa growth promotion and transcriptional co-action with the full length AR and AR splice variants represent novel mechanisms of CR growth of PCa. This is significant since Stat5a/b activation may effectively be disrupted by pharmacological inhibitors of Jak2-Stat5a/b signaling pathway, thus providing a rapidly implementable therapeutic strategy for CR PCa. We will determine whether Stat5a/b gene amplification, alone or in combination with AR gene amplification may provide a new predictive marker for identification of patients with PCa likely to progress to CR disease and would benefit from early aggressive intervention. Furthermore, Stat5a/b gene amplification may provide a predictive marker of responsiveness to therapies targeting Jak2-Stat5 signaling pathway. In summary, the proposed research may provide new strategies for improved and individualized therapy for PCa patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA113580-09
Application #
8828101
Study Section
Tumor Cell Biology Study Section (TCB)
Program Officer
Woodhouse, Elizabeth
Project Start
2005-07-01
Project End
2017-03-31
Budget Start
2015-04-01
Budget End
2016-03-31
Support Year
9
Fiscal Year
2015
Total Cost
$267,260
Indirect Cost
$82,484
Name
Thomas Jefferson University
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
053284659
City
Philadelphia
State
PA
Country
United States
Zip Code
19107
Maranto, Cristina; Udhane, Vindhya; Hoang, David T et al. (2018) STAT5A/B Blockade Sensitizes Prostate Cancer to Radiation through Inhibition of RAD51 and DNA Repair. Clin Cancer Res 24:1917-1931
Hurrell, Sarah L; McGarry, Sean D; Kaczmarowski, Amy et al. (2018) Optimized b-value selection for the discrimination of prostate cancer grades, including the cribriform pattern, using diffusion weighted imaging. J Med Imaging (Bellingham) 5:011004
McGarry, Sean D; Hurrell, Sarah L; Iczkowski, Kenneth A et al. (2018) Radio-pathomic Maps of Epithelium and Lumen Density Predict the Location of High-Grade Prostate Cancer. Int J Radiat Oncol Biol Phys 101:1179-1187
Hoang, David T; Iczkowski, Kenneth A; Kilari, Deepak et al. (2017) Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles. Oncotarget 8:3724-3745
Li, Guangyuan; Hayward, Isaac N; Jenkins, Brittany R et al. (2016) Peptidylarginine Deiminase 3 (PAD3) Is Upregulated by Prolactin Stimulation of CID-9 Cells and Expressed in the Lactating Mouse Mammary Gland. PLoS One 11:e0147503
Wang, Yuan; Lieberman, Rachel; Pan, Jing et al. (2016) miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1. Mol Cancer 15:70
Singh, Amrita; Fedele, Carmine; Lu, Huimin et al. (2016) Exosome-mediated Transfer of ?v?3 Integrin from Tumorigenic to Nontumorigenic Cells Promotes a Migratory Phenotype. Mol Cancer Res 14:1136-1146
Liao, Zhiyong; Gu, Lei; Vergalli, Jenny et al. (2015) Structure-Based Screen Identifies a Potent Small Molecule Inhibitor of Stat5a/b with Therapeutic Potential for Prostate Cancer and Chronic Myeloid Leukemia. Mol Cancer Ther 14:1777-93
Talati, Pooja G; Gu, Lei; Ellsworth, Elyse M et al. (2015) Jak2-Stat5a/b Signaling Induces Epithelial-to-Mesenchymal Transition and Stem-Like Cell Properties in Prostate Cancer. Am J Pathol 185:2505-22
Hoang, David T; Gu, Lei; Liao, Zhiyong et al. (2015) Inhibition of Stat5a/b Enhances Proteasomal Degradation of Androgen Receptor Liganded by Antiandrogens in Prostate Cancer. Mol Cancer Ther 14:713-26

Showing the most recent 10 out of 30 publications